Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Wuxi Biologics (Cayman) ( (HK:2269) ) has provided an update.
WuXi Biologics (Cayman) Inc. has announced a change in its principal place of business in Hong Kong, effective January 10, 2025, to Room 1910, 19/F, Lee Garden One, Causeway Bay. This relocation reflects the company’s ongoing strategy to optimize operational efficiency and enhance its presence in the Hong Kong market, which may have implications for stakeholders involved in the company’s regional operations.
More about Wuxi Biologics (Cayman)
WuXi Biologics (Cayman) Inc. operates in the biopharmaceutical industry, providing open-access biologics technology platforms. The company focuses on enabling global partners to discover, develop, and manufacture biologics from concept to commercialization.
YTD Price Performance: -8.10%
Average Trading Volume: 4,262
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $8.7B
For a thorough assessment of 2269 stock, go to TipRanks’ Stock Analysis page.